Sanofi and CD&R have signed a share purchase agreement for the sale of a 50% stake in the consumer health business.

Sanofi (NASDAQ:SNY) is a global healthcare company headquartered in Paris, France. It specializes in medical treatments for ...

Sanofi ( NASDAQ: SNY) has entered a share purchase agreement in relation to the sale of a 50% controlling stake in Opella, ...

Sanofi is closer to selling a 50% controlling stake in the consumer health business, Opella to private equity Clayton ...

The pharma signed an agreement handing PE firm CD&R a 50% stake in its Capella unit. Elsewhere, Gilead and Ultragenyx secured ...

Sanofi's deep partnership with OpenAI could be a huge differentiating factor. Check out why I rate SNY stock a buy.

Biopharma doubles down on immunology and inflammation as companies target new pathways and seek to improve on current options ...

The company was founded in 1973 and is headquartered in Paris, France. Read More on SNYNF: Sanofi NewsMORE Related Stocks Indices ...

Regeneron and Sanofi said an FDA green light would make Dupixent the first targeted medicine in the U.S. for bullous pemphigoid, a debilitating and relapsing skin disease with underlying type 2 ...

Sanofi could be "bit more" active with M&A in near future, CFO says Sanofi's R&D spending to see limited increase in 2025 Beyfortus sales double, Dupixent sales miss estimates Jan 30 - Sanofi ...

Given Opella’s significant economic contribution to France, Sanofi’s divestment prompted concerns in the country about the potential loss of a strategic asset to a US company. The Bpifrance ...

Tarrytown, N.Y., biotechnology company Regeneron created Dupixent and markets it jointly in the U.S. with France's Sanofi under a 2007 collaboration agreement, while Sanofi markets the product ...